Page 3«..2345..10..»

Archive for the ‘Hypogonadism’ Category

Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade – Owned

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

For detailed insights on enhancing your product footprint, request for a Sample Report herehttps://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region.

In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

For in-depth competitive analysis, Check Pre-Book herehttps://www.persistencemarketresearch.com/checkout/29509

Reasons to Purchase this Report:

Accuracy and QualityOur reports strive to offer superior quality reports based on authentic and accurate findings.Customer SatisfactionWe aim to ensure that our clients research needs are met with customized, top-of-the-line solutions.Unmatched ExpertiseOur analysts and consultants are among the best in their field and promise to deliver excellent market intelligence.360-degree AnalysisWe leave no stone unturned to give clients an exhaustive coverage of the industry.

Our client success stories feature a range of clients fromFortune 500 companiesto fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

About Us :

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources.

Contact Us

Persistence Market ResearchU.S. Sales Office305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA-Canada Toll-Free: 800-961-0353E-mail id-[emailprotected]Website:www.persistencemarketresearch.com

Excerpt from:
Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned

Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis…

The global Male Hypogonadism Therapy Market is showing promising signs that can be explored well in the coming days to achieve a notable valuation by the end of 2020. The process would also witness a growth by % CAGR in between 2020 to 2026. The report is expected to consider the time-frame as the forecast period and it would deal with the market accordingly. Growth-inducing factors have been monitored closely in the report to gauge well the progress of the market. Each factor can play a significant role and has been given proper space on the basis of which the market can devise strategies. It has tracked various associated fields as well to get a proper map of how these end user industries are impacting the market and can take the market forward. The report has credibility as it banks on the expertise of adept researchers who fetch numbers from a pool of information and sieve them as per the requirement. In the process, they have gone through the market by having it analyzed on top-down and bottom-up basis.

The major player in global Male Hypogonadism Therapy market includes:

Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD, and more

Get a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-male-hypogonadism-therapy-market-size-status-and-forecast-2020-2026?utm_source=farmersledger&utm_medium=39

The segmentation plays a prominent role in dealing with the growth of the Male Hypogonadism Therapy Market where various types and applications are promoting better understanding of the market. This segmentation has a strong foundation in volume-wise and value-wise data which backs the process of understanding the market scenario with numbers. The market has been combed through properly to get all the factors in line. The report has been enriched interviews as a first hand method of getting data. These interviews include chats with top market players, market analysts, distributors, people in the field of research and development and others owing to which the reliability of the report has increased significantly.

Regional market analysis of the report has backed the study of different regions as an attempt to understand growth pockets that can be beneficial for the market. The regional analysis has import, export, and other processes covered. Players who are getting involved in the market for a better growth are looking for these growth pockets to capitalize on the opportunities provided and find new scopes for growth. Certain countries have been tracked in detail to monitor them closely as they can be major markets in the coming years. Benefits like better infrastructure, cost-effective labor, access to raw materials, they offer have become luring factors for many market players and they want to expand their business to these regions to increase their profit margin.

If you have any special requirements about Male Hypogonadism Therapy Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-male-hypogonadism-therapy-market-size-status-and-forecast-2020-2026?utm_source=farmersledger&utm_medium=39

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read this article:
Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis...

QOL and body composition benefits seen with novel oral T treatment – Urology Times

New data from phase 3 clinical trials provide further evidence supporting the safety and effectiveness of the first-to-market oral testosterone undecanoate treatment for hypogonadism (Jatenzo), reported Stanton Honig, MD.

Honig presented results for secondary end points from 2 randomized studies comparing the lipoprotein-coated testosterone undecanoate formulation with topical testosterone treatments showing that both the oral and gel products were associated with statistically significant improvements in psychosocial well-being and bone and body composition parameters. Safety analyses showed the oral testosterone undecanoate was associated with a modest increase in blood pressure, which was slightly higher in men with hypertension at study entry than in men with normal blood pressure and that neither the oral nor gel testosterones had any significant effect on liver function test results.

This novel formulation of testosterone undecanoate is a first-in-class oral testosterone replacement that does not have liver issues, said Honig, professor of clinical urology and director, Mens Health, Yale University School of Medicine, New Haven, Connecticut.

Taken twice daily, it provides hypogonadal men with total testosterone concentrations in the mid-eugonadal range. Its safety profile is generally consistent with injectable and topical testosterone preparations, although the product labeling for oral testosterone undecanoate includes a black box warning about the potential for increased blood pressure. The data collected in the oral testosterone undecanoate studies underscore the need to check blood pressure at some point in men who are started on this therapy, especially those who are hypertensive at baseline.

The 2 trials comprised a 4-month study and a 12-month investigation. Eligibility criteria were similar in the 2 trials. Men ages 18 to 65 years (to 75 years in the 12-month study) were included if they had hypogonadism (serum testosterone <300 ng/dL on 2 morning samples approximately 7 days apart), had signs and symptoms consistent with hypogonadism, and were either naive to or underwent washout from testosterone therapy.

The 4-month study randomized 222 men 3:1 to oral testosterone undecanoate 237 mg twice daily or once-daily topical testosterone solution. A total of 325 men were randomized 1:1 to oral testosterone undecanoate 200 mg twice daily or topical testosterone gel in the 12-month trial. Dose adjustments were allowed based on serum testosterone levels.

The 4 treatment groups were similar with respect to demographics and clinical characteristics in terms of baseline age, body mass index, comorbidities (prediabetes, diabetes, and hypertension), and mean baseline testosterone levels. Time-weighted average testosterone concentration increased to reach mid-eugonadal levels in all 4 treatment groups, with values ranging from 425 ng/dL to 524 ng/dL across all 4 study groups.

Data on psychosocial well-being were collected in both trials using the Psychosexual Daily Questionnaire. Results showed statistically significant improvements from baseline to study completion in mood, sexual desire, weekly sexual activity, and sexual energy with and without a partner with both the oral and topical treatments, Honig reported.

General well-being was evaluated in the 12-month study using the 36-Item Short Form Health Survey questionnaire. In the individual domains, statistically significant improvements were achieved in both the oral testosterone undecanoate and testosterone gel group and occurred in physical functioning, physical and emotional role limitation, social functioning, and bodily pain.

Changes in body composition parameters were also investigated in the 12-month study. The results for the oral testosterone undecanoate group showed spine bone mineral density, hip bone mineral density, lean body mass, and fat mass all improved significantly from baseline at 6 months with further improvements achieved at month 12.

Both the oral testosterone undecanoate and topical testosterone treatments were associated with minimal increases in serum prostate-specific antigen. Overall, the oral and topical treatments were associated with an increase of hematocrit in approximately 5% to 6% of patients.

Importantly, there were no clinical events associated with the hematocrit increases in the oral testosterone undecanoate or the testosterone gel group, nor did any patient discontinue treatment because of elevated hematocrit, Honig said.

Changes in blood pressure were followed using ambulatory monitoring. Among men treated with oral testosterone undecanoate, mean changes in 24-hour systolic and diastolic blood pressure were approximately 5 mm Hg and 2.5 mm Hg, respectively. Comparisons between men with and without hypertension at baseline showed that the average change was slightly higher in the hypertensive group.

Honig said, It is unclear whether the blood pressure rise is just for oral testosterone undecanoate or a general class effect, as it has been seen with subcutaneous testosterone preparations as well. Most importantly, both oral testosterone undecanoate and topical gel groups showed no significant changes in liver enzyme measurements over a 12-month period.

Disclosure: Honig is a consultant to Clarus Therapeutics and Endo.

Originally posted here:
QOL and body composition benefits seen with novel oral T treatment - Urology Times

Novel oral testosterone therapy shows liver health benefits – Urology Times

A novel lymphatically delivered oral testosterone undecanoate (Tlando) is a fixed-dose, well-tolerated, and effective treatment for hypogonadism with liver health benefits that clearly differentiate it from the potentially hepatotoxic oral methyltestosterone, reported Irwin Goldstein, MD, at the American Urological Association 2020 Virtual Experience.

This innovative product has exciting, paradigm-shifting potential for treating men with low testosterone, said Goldstein, director of Sexual Medicine at Alvarado Hospital in San Diego, California, and clinical professor of surgery at the University of California San Diego.

It offers the opportunity to provide safe, effective, and well-tolerated testosterone replacement through the oral route that is the generally preferred method for medication administration. In addition, available data indicate that it not only avoids the adverse hepatic effects that have historically limited use of oral testosterone, but it improves markers of nonalcoholic fatty liver disease [NAFLD] that is a serious and prevalent condition. Low testosterone (ie, hypogonadism) is common in males with NAFLD.

Methyltestosterone is prone to cause liver toxicity with oral ingestion because it is directly transported to the liver through the portal vein, Goldstein said. In contrast, the lymphatically delivered oral testosterone undecanoate is a nonmethylated prodrug of endogenous testosterone, found in Tlando, that avoids first-pass metabolism in the liver and enters the systemic circulation via the lymphatics.

The safety and efficacy of Tlando for treating men with low testosterone was investigated in the 1-year SOAR trial that included 210 men who received the investigational product and a control group of 105 patients treated with topical testosterone gel.

Results from SOAR showed that the oral testosterone undecanoate was associated with a significantly greater increase in free testosterone levels compared with the topical product, and it improved key mental and sexual domains, reported Goldstein, who was an investigator in SOAR and an earlier dosing study.

Safety data in the study included measurement of liver enzymes and showed that reductions were consistently achieved in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and -glutamyl transferase among men who had elevated levels of those markers of liver injury at baseline. Rates of normalization for those 4 enzymes ranged from 31% for -glutamyl transferase to 67% for alkaline phosphatase.

40% reduction in liver fat at 4 months

Additional data on the liver effects of the novel testosterone undecanoate product were obtained in a smaller separate trial of men with hypogonadism. Using the objective Magnetic Resonance Imaging Proton Density Fat Fraction technique to measure liver fat percentage, it found that after 4 months, men with NAFLD at baseline achieved an approximately 40% reduction in liver fat. In addition, more than 75% of men who entered the study with NAFLD were considered responders to the oral testosterone undecanoate based on achieving a 30% or greater reduction in the percentage of liver fat.

In addition, the percentage of patients categorized as NAFLD-free rose during the study and nearly doubled by its conclusion, increasing from 34% at baseline to reach 63% at 16 weeks.

Interestingly, the higher the baseline body mass index, the greater the reduction in liver fat achieved with Tlando treatment, and it appears that the improvement in liver fat does not appear to be explained by any decrease in body weight, Goldstein said.

Disclosures: Lipocine Inc provided funding for the study. Goldstein is on the consultant/advisory board of Lipocine Inc, does research for AbbVie Inc and Marius Pharmaceuticals LLC, is on the Clarus Therapeutics, Inc speakers bureau, and receives writing support from Endo International.

See the original post here:
Novel oral testosterone therapy shows liver health benefits - Urology Times

Rising infertility related issues are boosting the growth of the Human Chorionic Gonadotropin (HCG) Market – Day Web Chronicle

Human chorionic gonadotropin (hCG) hails from the group of gonadotropin hormones and is normally created by the placenta. hCG hormone plays a vital job after the development of the incipient organism, and thus has increased huge footing throughout the years for the treatment of fruitlessness in men and women.

Sample Link Here: https://www.globalinforeports.com/request-sample/1070128

Ascend in the incidence of male hypogonadism among the aged populace is the key factor driving the market development. Likewise, increment in footing picked up by hCG among social insurance experts and patients would enhance the market development. Nonetheless, alerts and admonitions gave by the FDA relating to the symptoms of hCG treatment is anticipated to hamper the market development.

North America was the significant revenue generator in 2017 and is foreseen to keep up its predominance all through the conjecture time frame. This is ascribed to noteworthy increment in occurrence of infertility related issues both in females and male.

Purchase Link Here: https://www.globalinforeports.com/checkout/1070128

See original here:
Rising infertility related issues are boosting the growth of the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle

Male Hypogonadism Therapy Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 – Weekly Wall

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Covid-19 Impact on Male Hypogonadism Therapy market. It informs readers about key trends and opportunities in the global Covid-19 Impact on Male Hypogonadism Therapy market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Covid-19 Impact on Male Hypogonadism Therapy market.

Key companies operating in the global Covid-19 Impact on Male Hypogonadism Therapy market include , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Male Hypogonadism Therapy

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1734929/covid-19-impact-on-global-male-hypogonadism-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Covid-19 Impact on Male Hypogonadism Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Covid-19 Impact on Male Hypogonadism Therapy Market Segment By Type:

, Parenteral, Transdermal, Oral, Other

Global Covid-19 Impact on Male Hypogonadism Therapy Market Segment By Application:

, Hospitals, Drugstores, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Covid-19 Impact on Male Hypogonadism Therapy market.

Key companies operating in the global Covid-19 Impact on Male Hypogonadism Therapy market include , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Male Hypogonadism Therapy

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1734929/covid-19-impact-on-global-male-hypogonadism-therapy-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Male Hypogonadism Therapy Revenue1.4 Market Analysis by Type 1.4.1 Global Male Hypogonadism Therapy Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Parenteral 1.4.3 Transdermal 1.4.4 Oral 1.4.5 Others1.5 Market by Application 1.5.1 Global Male Hypogonadism Therapy Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Drugstores 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Male Hypogonadism Therapy Industry Impact 1.6.1 How the Covid-19 is Affecting the Male Hypogonadism Therapy Industry 1.6.1.1 Male Hypogonadism Therapy Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Male Hypogonadism Therapy Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Male Hypogonadism Therapy Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Male Hypogonadism Therapy Market Perspective (2015-2026)2.2 Male Hypogonadism Therapy Growth Trends by Regions 2.2.1 Male Hypogonadism Therapy Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Male Hypogonadism Therapy Historic Market Share by Regions (2015-2020) 2.2.3 Male Hypogonadism Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Male Hypogonadism Therapy Market Growth Strategy 2.3.6 Primary Interviews with Key Male Hypogonadism Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Male Hypogonadism Therapy Players by Market Size 3.1.1 Global Top Male Hypogonadism Therapy Players by Revenue (2015-2020) 3.1.2 Global Male Hypogonadism Therapy Revenue Market Share by Players (2015-2020) 3.1.3 Global Male Hypogonadism Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Male Hypogonadism Therapy Market Concentration Ratio 3.2.1 Global Male Hypogonadism Therapy Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Male Hypogonadism Therapy Revenue in 20193.3 Male Hypogonadism Therapy Key Players Head office and Area Served3.4 Key Players Male Hypogonadism Therapy Product Solution and Service3.5 Date of Enter into Male Hypogonadism Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Male Hypogonadism Therapy Historic Market Size by Type (2015-2020)4.2 Global Male Hypogonadism Therapy Forecasted Market Size by Type (2021-2026) 5 Male Hypogonadism Therapy Breakdown Data by Application (2015-2026)5.1 Global Male Hypogonadism Therapy Market Size by Application (2015-2020)5.2 Global Male Hypogonadism Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Male Hypogonadism Therapy Market Size (2015-2020)6.2 Male Hypogonadism Therapy Key Players in North America (2019-2020)6.3 North America Male Hypogonadism Therapy Market Size by Type (2015-2020)6.4 North America Male Hypogonadism Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Male Hypogonadism Therapy Market Size (2015-2020)7.2 Male Hypogonadism Therapy Key Players in Europe (2019-2020)7.3 Europe Male Hypogonadism Therapy Market Size by Type (2015-2020)7.4 Europe Male Hypogonadism Therapy Market Size by Application (2015-2020) 8 China8.1 China Male Hypogonadism Therapy Market Size (2015-2020)8.2 Male Hypogonadism Therapy Key Players in China (2019-2020)8.3 China Male Hypogonadism Therapy Market Size by Type (2015-2020)8.4 China Male Hypogonadism Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Male Hypogonadism Therapy Market Size (2015-2020)9.2 Male Hypogonadism Therapy Key Players in Japan (2019-2020)9.3 Japan Male Hypogonadism Therapy Market Size by Type (2015-2020)9.4 Japan Male Hypogonadism Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Male Hypogonadism Therapy Market Size (2015-2020)10.2 Male Hypogonadism Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Male Hypogonadism Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Male Hypogonadism Therapy Market Size by Application (2015-2020) 11 India11.1 India Male Hypogonadism Therapy Market Size (2015-2020)11.2 Male Hypogonadism Therapy Key Players in India (2019-2020)11.3 India Male Hypogonadism Therapy Market Size by Type (2015-2020)11.4 India Male Hypogonadism Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Male Hypogonadism Therapy Market Size (2015-2020)12.2 Male Hypogonadism Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Male Hypogonadism Therapy Market Size by Type (2015-2020)12.4 Central & South America Male Hypogonadism Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Eli Lilly 13.1.1 Eli Lilly Company Details 13.1.2 Eli Lilly Business Overview and Its Total Revenue 13.1.3 Eli Lilly Male Hypogonadism Therapy Introduction 13.1.4 Eli Lilly Revenue in Male Hypogonadism Therapy Business (2015-2020)) 13.1.5 Eli Lilly Recent Development13.2 Pfizer 13.2.1 Pfizer Company Details 13.2.2 Pfizer Business Overview and Its Total Revenue 13.2.3 Pfizer Male Hypogonadism Therapy Introduction 13.2.4 Pfizer Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.2.5 Pfizer Recent Development13.3 AbbVie 13.3.1 AbbVie Company Details 13.3.2 AbbVie Business Overview and Its Total Revenue 13.3.3 AbbVie Male Hypogonadism Therapy Introduction 13.3.4 AbbVie Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.3.5 AbbVie Recent Development13.4 Novo Nordisk 13.4.1 Novo Nordisk Company Details 13.4.2 Novo Nordisk Business Overview and Its Total Revenue 13.4.3 Novo Nordisk Male Hypogonadism Therapy Introduction 13.4.4 Novo Nordisk Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.4.5 Novo Nordisk Recent Development13.5 Merck KGaA 13.5.1 Merck KGaA Company Details 13.5.2 Merck KGaA Business Overview and Its Total Revenue 13.5.3 Merck KGaA Male Hypogonadism Therapy Introduction 13.5.4 Merck KGaA Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.5.5 Merck KGaA Recent Development13.6 Mylan 13.6.1 Mylan Company Details 13.6.2 Mylan Business Overview and Its Total Revenue 13.6.3 Mylan Male Hypogonadism Therapy Introduction 13.6.4 Mylan Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.6.5 Mylan Recent Development13.7 Bayer 13.7.1 Bayer Company Details 13.7.2 Bayer Business Overview and Its Total Revenue 13.7.3 Bayer Male Hypogonadism Therapy Introduction 13.7.4 Bayer Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.7.5 Bayer Recent Development13.8 Teva 13.8.1 Teva Company Details 13.8.2 Teva Business Overview and Its Total Revenue 13.8.3 Teva Male Hypogonadism Therapy Introduction 13.8.4 Teva Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.8.5 Teva Recent Development13.9 Novartis 13.9.1 Novartis Company Details 13.9.2 Novartis Business Overview and Its Total Revenue 13.9.3 Novartis Male Hypogonadism Therapy Introduction 13.9.4 Novartis Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.9.5 Novartis Recent Development13.10 Abbott 13.10.1 Abbott Company Details 13.10.2 Abbott Business Overview and Its Total Revenue 13.10.3 Abbott Male Hypogonadism Therapy Introduction 13.10.4 Abbott Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.10.5 Abbott Recent Development13.11 Roche 10.11.1 Roche Company Details 10.11.2 Roche Business Overview and Its Total Revenue 10.11.3 Roche Male Hypogonadism Therapy Introduction 10.11.4 Roche Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.11.5 Roche Recent Development13.12 Endo International 10.12.1 Endo International Company Details 10.12.2 Endo International Business Overview and Its Total Revenue 10.12.3 Endo International Male Hypogonadism Therapy Introduction 10.12.4 Endo International Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.12.5 Endo International Recent Development13.13 Ipsen 10.13.1 Ipsen Company Details 10.13.2 Ipsen Business Overview and Its Total Revenue 10.13.3 Ipsen Male Hypogonadism Therapy Introduction 10.13.4 Ipsen Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.13.5 Ipsen Recent Development13.14 ANI Pharmaceuticals 10.14.1 ANI Pharmaceuticals Company Details 10.14.2 ANI Pharmaceuticals Business Overview and Its Total Revenue 10.14.3 ANI Pharmaceuticals Male Hypogonadism Therapy Introduction 10.14.4 ANI Pharmaceuticals Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.14.5 ANI Pharmaceuticals Recent Development13.15 TherapeuticsMD 10.15.1 TherapeuticsMD Company Details 10.15.2 TherapeuticsMD Business Overview and Its Total Revenue 10.15.3 TherapeuticsMD Male Hypogonadism Therapy Introduction 10.15.4 TherapeuticsMD Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.15.5 TherapeuticsMD Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original here:
Male Hypogonadism Therapy Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 - Weekly Wall

Jacobs School appoints new chair of Obstetrics and Gynecology – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

Sarah L. Berga has been appointed as the new chair of the Department of Obstetrics and Gynecology in the Jacobs School of Medicine and Biomedical Sciences at UB. She will also serve as president of UBMD Obstetrics & Gynecology, and medical director of Obstetrics and Gynecology and Maternal Fetal Medicine Program Development for Kaleida Health.

Bergas appointments, which began June 1, were announced by Michael E. Cain, vice president for health sciences and dean of the Jacobs School.

Dr. Berga rapidly emerged as our top candidate possessing the administrative, scientific, clinical, leadership and visionary skills needed to move the department forward, expand the departments basic and clinical research programs to fulfill the Jacobs Schools strategic goals, enhance the excellence of the departments graduate medical education and mentored research training programs, and develop and align a comprehensive clinical program at Kaleida Health and our community, Cain said.

Berga will succeed Vanessa Barnabei, who had served as chair since 2012. Barnabei has accepted a new position at the Jacobs School as associate dean for faculty advancement and development. In this new role, she will work with department chairs and chiefs, senior leaders in the offices of Faculty Affairs, the Medical Education and Education Research Institute, Diversity and Inclusion, Graduate Medical Education, Research Integration and others both within the school and beyond to promote opportunities for faculty scholarly activity, academic promotion, retention and wellness.She will continue in her clinical capacity, seeing patients at UBMD Obstetrics & Gynecology.

Berga comes to UB from the University of Utah School of Medicines Department of Obstetrics and Gynecology, where she served as professor and director of the Division of Reproductive Endocrinology and Infertility for two years.

(Berga) is an accomplished clinician, physician-investigator and educator, Cain said.

In addition, she is a diplomat of the National Board of Medical Examiners, the American Board of Obstetrics and Gynecology and the American Board of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility.

I am totally thrilled to be joining the Jacobs School of Medicine and Biomedical Sciences, Kaleida Health and UBMD Obstetrics & Gynecology, Berga said. I was excited to be asked to look at the position; it is an amazing opportunity to build on what has been achieved to date at UB in the Jacobs School and in obstetrics, gynecology and womens health in particular.The new Oishei hospital is magnificent and the partnership with UB presents an unparalleled synergistic opportunity to expand programs, to conduct translational and clinical research, and to educate the next generation of womens health physicians and providers of all types.

Caring for patients through UBMD Obstetrics & Gynecology and Kaleida Health, Berga specializes in reproductive hormones, infertility and stress-induced hypothalamic hypogonadism (amenorrhea). Her clinical interests include in vitro fertilization (IVF), which she will be introducing to the UBMD practice, as well as perimenopause, hormone therapies and polycystic ovary syndrome.

Her research interests include determining the neuroendocrine mechanisms mediating stress-induced reproductive compromise and the impact of sex hormones on brain health in human and monkey models using neuroimaging and delineation of hormonal and cognitive patterns. Her research endeavors have been consistently funded by the National Institutes of Health, research foundations and industry.

Ive always been interested in how mindset attitudes and behaviors influence hormones and reproductive hormones in particular, Berga said.Her current research collaborations include understanding how stress and hormones influence brain and heart health in women.

Berga has authored or co-authored over 150 peer-reviewed scientific articles and written over 85 book chapters. In 2020, she was awarded the DeCherney Society Lifetime Distinguished Service Award by the Society for Reproductive Investigation. She currently serves as an associate editor for Human Reproduction Update. She has served on many NIH grant review committees.

Berga received her bachelors degree from the University of Virginia and her medical degree from the University of Virginia School of Medicine. She completed a residency in obstetrics and gynecology at Harvard Medical School, followed by a fellowship in reproductive endocrinology at University of California, San Diego School of Medicine.

She served as assistant professor, associate professor and professor at the University of Pittsburgh School of Medicine. She has also served as the James Robert McCord Professor and Chair in the Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology and Infertility at the Emory University School of Medicine.

Read more from the original source:
Jacobs School appoints new chair of Obstetrics and Gynecology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Demanded Report on Male Hypogonadism Market Analysis Forecast with Leading Key Players: AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli…

The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

Some of the key players of Male Hypogonadism Market:AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli Lilly and Company Ltd., Endo International plc., Merck & Co., Inc., Ferring, Finox Biotech, IBSA Institut Biochimque SA, Laboratoires Genevrier, Teva Pharmaceutical Industries Ltd.

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00012659727/sample

Male Hypogonadism Market report provides in-depth statistics and analysis available on the market status of the Male Hypogonadism key players and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Male Hypogonadism market. It contains the analysis of drivers, challenges, and restraints impacting the industry.

Type Segmentation:Klinefelters Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

DRUG DELIVERY Segmentation:Topical Gels

Injectables

Transdermal Patches

Others

Major Regions play vital role in Male Hypogonadism market are:North America, Europe, China, Japan, Middle East & Africa, India, South America, Others

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00012659727/discount

Research objectives

To study and analyze the global Die Cutting Machines consumption (value & volume) by key regions/countries, type and application, history data, and forecast.

To understand the structure of Die Cutting Machines market by identifying its various subsegments.

Focuses on the key global Die Cutting Machines manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Die Cutting Machines with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Die Cutting Machines submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Fundamentals of Table of Content:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

Chapter 4 Market Landscape

Chapter 5 Market Trend Analysis

Chapter 6 Industry Chain Analysis

Chapter 7 Latest Market Dynamics

Chapter 8 Trading Analysis

Chapter 9 Historical and Current Interposer in North America

Continue for TOC

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00012659727/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Excerpt from:
Demanded Report on Male Hypogonadism Market Analysis Forecast with Leading Key Players: AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli...

COVID-19: Responding to the business impacts of Global Male Hypogonadism Market : Current Trends and Future Estimations to Elucidate Imminent…

Analysis of the Global Male Hypogonadism Market

A recently published market report on the Male Hypogonadism market highlights the pitfalls that companies might come across due to the unprecedented outbreak of COVID-19 (Coronavirus). Buyers can request comprehensive market analysis of Coronavirus and its impact on the Male Hypogonadism market to mitigate revenue losses.

This market research report on the Male Hypogonadism market published by Male Hypogonadism derives current insights about the competitive landscape of the Male Hypogonadism market. Further, the report unfolds detailed analysis of different segments of the Male Hypogonadism market and offers a thorough understanding of the growth potential of each market segment over the assessment period (20XX-20XX).

According to the analysts at Male Hypogonadism , the Male Hypogonadism market is predicted to register a CAGR growth of ~XX% during the assessment and reach a value of ~US$ XX by the end of 20XX. The report analyzes the micro and macro-economic factors that are projected to influence the growth of the Male Hypogonadism market in the coming decade.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2677738&source=atm

Key Insights Highlighted in the Report

Segmentation of the Male Hypogonadism Market

The presented report elaborate on the Male Hypogonadism market into different segments and ponders over the current and future business potentials of each segment. The report showcases the year-on-year growth of each segment and ponders upon the different factors that are likely to influence the growth of each market segment.

The various segments of the Male Hypogonadism market explained in the report include:

Key market playersMajor competitors identified in this market include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:Testosterone Replacement TherapyGonadotropin-Releasing Hormones Therapy

Based on the Application:Kallmann SyndromeKlinefelters SyndromePituitary DisordersOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2677738&source=atm

Important doubts related to the Male Hypogonadism market clarified in the report:

Why Choose Male Hypogonadism

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2677738&licType=S&source=atm

Follow this link:
COVID-19: Responding to the business impacts of Global Male Hypogonadism Market : Current Trends and Future Estimations to Elucidate Imminent...

Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| – Jewish Life News

QY Research as of late produced a research report titled, Transdermal Testosterone . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Transdermal Testosterone market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Transdermal Testosterone market are: , AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1536918/global-transdermal-testosterone-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Transdermal Testosterone Market Segment By Type:

, Gel, Patch, Solution

Global Transdermal Testosterone Market Segment By Application:

, Primary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Transdermal Testosterone market include , AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1536918/global-transdermal-testosterone-market

TOC

Table of Contents 1 Transdermal Testosterone Market Overview1.1 Transdermal Testosterone Product Overview1.2 Transdermal Testosterone Market Segment by Type1.2.1 Gel1.2.2 Patch1.2.3 Solution1.3 Global Transdermal Testosterone Market Size by Type (2015-2026)1.3.1 Global Transdermal Testosterone Market Size Overview by Type (2015-2026)1.3.2 Global Transdermal Testosterone Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Transdermal Testosterone Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Transdermal Testosterone Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Transdermal Testosterone Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Transdermal Testosterone Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Transdermal Testosterone Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Transdermal Testosterone Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Transdermal Testosterone Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.2 Europe Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.4 Latin America Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Transdermal Testosterone Sales Breakdown by Type (2015-2026) 2 Global Transdermal Testosterone Market Competition by Company2.1 Global Top Players by Transdermal Testosterone Sales (2015-2020)2.2 Global Top Players by Transdermal Testosterone Revenue (2015-2020)2.3 Global Top Players Transdermal Testosterone Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Transdermal Testosterone Manufacturing Base Distribution, Sales Area, Product Type2.5 Transdermal Testosterone Market Competitive Situation and Trends2.5.1 Transdermal Testosterone Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Transdermal Testosterone Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transdermal Testosterone as of 2019)2.7 Date of Key Manufacturers Enter into Transdermal Testosterone Market2.8 Key Manufacturers Transdermal Testosterone Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Transdermal Testosterone Status and Outlook by Region (2015-2026)3.1 Global Transdermal Testosterone Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Transdermal Testosterone Market Size Market Share by Region (2015-2020)3.2.1 Global Transdermal Testosterone Sales Market Share by Region (2015-2020)3.2.2 Global Transdermal Testosterone Revenue Market Share by Region (2015-2020)3.2.3 Global Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Transdermal Testosterone Market Size Market Share by Region (2021-2026)3.3.1 Global Transdermal Testosterone Sales Market Share by Region (2021-2026)3.3.2 Global Transdermal Testosterone Revenue Market Share by Region (2021-2026)3.3.3 Global Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Transdermal Testosterone Market Size YoY Growth (2015-2026)3.4.1 North America Transdermal Testosterone Revenue YoY Growth (2015-2026)3.4.2 North America Transdermal Testosterone Sales YoY Growth (2015-2026)3.5 Asia-Pacific Transdermal Testosterone Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Transdermal Testosterone Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Transdermal Testosterone Sales YoY Growth (2015-2026)3.6 Europe Transdermal Testosterone Market Size YoY Growth (2015-2026)3.6.1 Europe Transdermal Testosterone Revenue YoY Growth (2015-2026)3.6.2 Europe Transdermal Testosterone Sales YoY Growth (2015-2026)3.7 Latin America Transdermal Testosterone Market Size YoY Growth (2015-2026)3.7.1 Latin America Transdermal Testosterone Revenue YoY Growth (2015-2026)3.7.2 Latin America Transdermal Testosterone Sales YoY Growth (2015-2026)3.8 Middle East and Africa Transdermal Testosterone Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Transdermal Testosterone Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Transdermal Testosterone Sales YoY Growth (2015-2026) 4 Global Transdermal Testosterone by Application4.1 Transdermal Testosterone Segment by Application4.1.1 Primary hypogonadism4.1.2 Hypogonadotropic hypogonadism4.1.3 Late-onset hypogonadism4.2 Global Transdermal Testosterone Sales by Application: 2015 VS 2020 VS 20264.3 Global Transdermal Testosterone Historic Sales by Application (2015-2020)4.4 Global Transdermal Testosterone Forecasted Sales by Application (2021-2026)4.5 Key Regions Transdermal Testosterone Market Size by Application4.5.1 North America Transdermal Testosterone by Application4.5.2 Europe Transdermal Testosterone by Application4.5.3 Asia-Pacific Transdermal Testosterone by Application4.5.4 Latin America Transdermal Testosterone by Application4.5.5 Middle East and Africa Transdermal Testosterone by Application 5 North America Transdermal Testosterone Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Transdermal Testosterone Sales Market Share by Country (2015-2020)5.1.2 North America Transdermal Testosterone Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Transdermal Testosterone Sales Market Share by Country (2021-2026)5.2.2 North America Transdermal Testosterone Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Transdermal Testosterone Market Size YoY Growth (2015-2026)5.3.2 Canada Transdermal Testosterone Market Size YoY Growth (2015-2026) 6 Europe Transdermal Testosterone Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Transdermal Testosterone Sales Market Share by Country (2015-2020)6.1.2 Europe Transdermal Testosterone Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Transdermal Testosterone Sales Market Share by Country (2021-2026)6.2.2 Europe Transdermal Testosterone Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.2 France Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.3 U.K. Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.4 Italy Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.5 Russia Transdermal Testosterone Market Size YoY Growth (2015-2026) 7 Asia-Pacific Transdermal Testosterone Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Transdermal Testosterone Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Transdermal Testosterone Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Transdermal Testosterone Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Transdermal Testosterone Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.2 Japan Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.3 South Korea Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.4 India Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.5 Australia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.6 Taiwan Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.7 Indonesia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.8 Thailand Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.9 Malaysia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.10 Philippines Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.11 Vietnam Transdermal Testosterone Market Size YoY Growth (2015-2026) 8 Latin America Transdermal Testosterone Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Transdermal Testosterone Sales Market Share by Country (2015-2020)8.1.2 Latin America Transdermal Testosterone Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Transdermal Testosterone Sales Market Share by Country (2021-2026)8.2.2 Latin America Transdermal Testosterone Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Transdermal Testosterone Market Size YoY Growth (2015-2026)8.3.2 Brazil Transdermal Testosterone Market Size YoY Growth (2015-2026)8.3.3 Argentina Transdermal Testosterone Market Size YoY Growth (2015-2026) 9 Middle East and Africa Transdermal Testosterone Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Transdermal Testosterone Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Transdermal Testosterone Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Transdermal Testosterone Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Transdermal Testosterone Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Transdermal Testosterone Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Transdermal Testosterone Market Size YoY Growth (2015-2026)9.3.3 U.A.E Transdermal Testosterone Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Transdermal Testosterone Business10.1 AbbVie10.1.1 AbbVie Corporation Information10.1.2 AbbVie Description, Business Overview and Total Revenue10.1.3 AbbVie Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.1.4 AbbVie Transdermal Testosterone Products Offered10.1.5 AbbVie Recent Development10.2 Teva10.2.1 Teva Corporation Information10.2.2 Teva Description, Business Overview and Total Revenue10.2.3 Teva Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.2.5 Teva Recent Development10.3 Perrigo10.3.1 Perrigo Corporation Information10.3.2 Perrigo Description, Business Overview and Total Revenue10.3.3 Perrigo Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.3.4 Perrigo Transdermal Testosterone Products Offered10.3.5 Perrigo Recent Development10.4 Endo Pharmaceuticals10.4.1 Endo Pharmaceuticals Corporation Information10.4.2 Endo Pharmaceuticals Description, Business Overview and Total Revenue10.4.3 Endo Pharmaceuticals Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.4.4 Endo Pharmaceuticals Transdermal Testosterone Products Offered10.4.5 Endo Pharmaceuticals Recent Development10.5 Acerus Pharmaceuticals10.5.1 Acerus Pharmaceuticals Corporation Information10.5.2 Acerus Pharmaceuticals Description, Business Overview and Total Revenue10.5.3 Acerus Pharmaceuticals Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.5.4 Acerus Pharmaceuticals Transdermal Testosterone Products Offered10.5.5 Acerus Pharmaceuticals Recent Development10.6 Lupin10.6.1 Lupin Corporation Information10.6.2 Lupin Description, Business Overview and Total Revenue10.6.3 Lupin Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.6.4 Lupin Transdermal Testosterone Products Offered10.6.5 Lupin Recent Development10.7 Dr. Reddys Laboratories10.7.1 Dr. Reddys Laboratories Corporation Information10.7.2 Dr. Reddys Laboratories Description, Business Overview and Total Revenue10.7.3 Dr. Reddys Laboratories Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.7.4 Dr. Reddys Laboratories Transdermal Testosterone Products Offered10.7.5 Dr. Reddys Laboratories Recent Development10.8 Upsher-Smith Laboratories10.8.1 Upsher-Smith Laboratories Corporation Information10.8.2 Upsher-Smith Laboratories Description, Business Overview and Total Revenue10.8.3 Upsher-Smith Laboratories Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.8.4 Upsher-Smith Laboratories Transdermal Testosterone Products Offered10.8.5 Upsher-Smith Laboratories Recent Development10.9 Allergan10.9.1 Allergan Corporation Information10.9.2 Allergan Description, Business Overview and Total Revenue10.9.3 Allergan Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.9.4 Allergan Transdermal Testosterone Products Offered10.9.5 Allergan Recent Development10.10 Cipla Inc.10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Transdermal Testosterone Product Category, Application and Specification10.10.3 Cipla Inc. Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Cipla Inc. Recent Development 11 Transdermal Testosterone Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Transdermal Testosterone Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Transdermal Testosterone Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| - Jewish Life News

Scientists Discover New Sexual Hormone that Could Offer Better Fertility Treatments – Science Times

DailyMailreports that a team of Canadian researchers have discovered a new sex hormone in zebrafish. They say this discovery could lead to developing better fertility treatment options for humans.

The researchers successfully restored partial sexual function in genetically mutated zebrafish with a single injection. In their trial, the jab was able to enhance further the ability of the female fish to ovulate and lay her eggs.

The fish possessed about 70% genes similar to humans, which makes it the perfect lab models. According to researchers, the key to the process is a small-like-molecule produced by the fish. Moreover, this molecule is found in other animals and humans as well.

According to Vance Trudeau, the senior author of the study, they mutated two related genes and analyzed their effects on the zebrafish's sexual function. Trudeau is a Professor of Neuroendocrinology at the University of Ottawa, Canada.

Additionally, he said that they used genetically modified fish to search for other factors that could improve sexual function. The researchers looked for clues leaning toward either increased spawning in cultured fish species or helping with the search for new infertility treatments for humans.

The findings of the research were published in Proceedings of the National Academy of Sciences.

Read Also: Men with Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Finds

Professor Trudeau and his co-author Kim Mitchell had discovered new functions that facilitate how males and females interact while mating when they initially started studying the effects of gene mutations in zebrafish.

Using gene technology developed at the Chinese Academy of Sciences, in Wuhan, China, the researchers were able to mutate two related genes under the name secretogranin-2. It encodes the protein with the same name.

Trudeau said that the first step of their experiments was to perform the gene editing to reduce the zebrafish's sexual behaviour. Furthermore, they changed the secretogranin-2 genes through specific mutations. The authors of the study found that it significantly affected the ability of females and males to breed.

According to Trudeau, it severely reduced their sexual behaviour. At first, the fish appeared normal. However, when both sexes were put together, they completely ignored each other. He explained how normally the male and female fish would engage in a 'courtship ritual' in which the male would chase the female.

Generally after the courtship, the female dispenses her eggs to the water, and the male fertilizes them. However, in a sample of gene-edited zebrafish couples used in the study, the researchers found only one in ten were able to spawn.

The experiments showed that the fish carrying the delivered mutations were capable of producing sperm and eggs, but were dreadful at mating. According to Trudeau, it was the first evidence that showed the mutation of genes leading to the disruption of sexual behaviour in animals.

For the experiment's second stage, the researchers used a fragment of secretogranin-2 in an attempt to reverse the seeming incapacity to mate. The team was able to partially restore sexual function by a single injection of the secretoneurin peptideinto the fish's body.

The researchers revealed new genes that can determine reproduction. Furthermore, the secretoneurin peptide itself has been classified as a new hormone with possible connotations for future fertility research.

According to Trudeau, the large secretogranin-2 genes could produce several other hormone-like peptides with functions still left to be discovered. He added that it would be exciting to explore the subject in future projects further.

Also Read: COVID-19 Male Patients to Receive Female Sex Hormones Estrogen and Progesterone To See if They Could Help Reduce Severity

The rest is here:
Scientists Discover New Sexual Hormone that Could Offer Better Fertility Treatments - Science Times

COVID-19 Impact on Global Steroids Market 2020: Industry Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report to…

TheGlobal Steroids Market isexpected to grow at a CAGR of XX% during the forecast period, 2017-2025.Increase in geriatric population drives the androgens and anabolic steroids market, as older men are more prone to hypogonadism. Additionally, rise in obesity in men propels the global androgens and anabolic steroids market.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/484751

The increasing poor health status especially in the developing countries is projected to fuel the growth of the market during the forecast period. Moreover, rise in government initiatives for better health care is attributed to the growth of the global androgens and anabolic steroids market.This report analyses the future prospects of Global Steroids Market.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Complete report on Steroids Industry spread across 114 pages, profiling 09 companies and supported with tables and figures. Enquire for more at https://www.orianresearch.com/enquiry-before-buying/484751

Top Key Companies Analyzed in Global Steroids Market are PFIZER Novartis Merck Sanofi Johnson And Johnson GSK Astrazeneca Cipla Sumitomo

Key benefit of this report: This report provides current market trends and future growth expectations. This report examines the market size and changing competitive dynamics It covers information regarding key drivers, challenges or restraining market growth It provides a five-year forecast assessed on the basis market value chain, porters five forces, and supply chain management. Market factor analysis delivers treasured information regarding the possible purchasers and suppliers and understanding the stakeholders involved. This report incorporates data regarding companies and business decision by having complete insights on the markets and by creating in depth analysis of market segments.

Target audience: Suppliers R&D Institutes Technology providers Wholesalers Dealers

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/484751

Major Points Covered in Table of Contents:1. Executive Summary2. Demographic Overview3. Research Methodology4. Premium Insights5. Market Overview6. Market Factor Analysis7. Market Segment by Types8. Market Segment by Application9. Market Segment by Routes of Administration10. Market Segment by End User11 Market Segment by Regions12 Market Trends & Competitive Analysis

13 Company ProfilesAuthor ListDisclosure SectionResearch MethodologyData Source

Customization Service of the Report:

Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (832) 380-8827 | UK: +44 0161-818-8027Email:[emailprotected]

Website:www.orianresearch.com/

Read more:
COVID-19 Impact on Global Steroids Market 2020: Industry Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report to...

Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy – Yahoo Finance

RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two key patents related to its lead asset, Kyzatrex*. Kyzatrex is an oral Testosterone Replacement Therapy (TRT) that uses an innovative formulation to improve effectiveness and safety.

These allowed claims will provide strong IP protection to December 2030, over 8 years of potential commercial runway. They supplement Marius Pharmaceuticals already robust global patent portfolio for Kyzatrex, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand and other key markets, and pending applications in India, and US. Marius Pharmaceuticals patent portfolio includes filings that extend protection to 2033, with the potential to extend protection out to 2040.

The allowed claims protect Kyzatrex, an innovative formulation designed to increase bioavailability and provide a favorable pharmacokinetic (PK) profile compared to other therapeutic alternatives. Om Dhingra, Chief Executive Officer of Marius commented This innovation is truly exceptional as we have created a formulation with a unique PK profile which we believe drives important clinical significance.

Marius Pharmaceuticals Chief Financial Officer Shalin Shah said We are very pleased to strengthen the intellectual property portfolio for Kyzatrex and excited that it has tremendous potential to be differentiated and unique option in the TRT space. We are also drawing a line in the sand between a new treatment paradigm and old testosterone therapies.

Marius Pharmaceuticals has recently completed its pivotal Phase 3 study for Kyzatrex and intends to submit its New Drug Application (NDA) to the Food & Drug Administration (FDA).

About Kyzatrex

Kyzatrex is an experimental therapy for the treatment of primary and secondary hypogonadism (congenital or acquired). Testosterone is a crucial hormone that plays key roles in human growth and development and a wide range of other functions including metabolic and cardiovascular. Sources estimate that 15 million men in the United States suffer from hypogonadism, but only approximately 10% are currently treated. The co-morbidities of men suffering from hypogonadism are also a significant burden on patients and the healthcare system, these include Type 2 Diabetes and other serious chronic conditions.

Current marketed treatments are dominated by painful injections and messy topical applications with transference risk. Kyzatrex is an orally administered therapy, which avoids those drawbacks. Market research points to 93% of patients indicating they would ask their physician about Kyzatrex and more than half would consider a switch from their current regimen.

About Marius Pharmaceuticals

Marius pharmaceuticals is a cutting-edge biopharma company focusing on treating widespread conditions that have been triggered primarily through Androgen deficiency. Our pipeline consists of assets focused on inflammation while our commercial arm is at the forefront of data science technologies core to our commercialization of our lead asset Kyzatrex.

*Kyzatrex is a tentative Tradename currently under review with the FDA

For more information, contact:Shalin Shahshalin@mariuspharma.comwww.mariuspharma.com

Read the rest here:
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy - Yahoo Finance

The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 – 3rd Watch News

Analysis Report on Male Hypogonadism Market

A report on global Male Hypogonadism market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Male Hypogonadism Market.

Request Sample Report @https://www.mrrse.com/sample/15062?source=atm

Some key points of Male Hypogonadism Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Male Hypogonadism Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Male Hypogonadism Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Male Hypogonadism market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Male Hypogonadism market is analyzed and depicted in the report.

The global Male Hypogonadism market segment by manufacturers include

Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at PMR, which ensures higher accuracy. PMRs research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by PMRs industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/15062?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Male Hypogonadism economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/15062?source=atm

Benefits of Purchasing Male Hypogonadism Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the rest here:
The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 - 3rd Watch News

Men With Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Fi – Science Times

Scientists have found in a new study that men who have lower levels of testosterone have a higher risk of dying from coronavirus if they ever catch the disease. In the study, researchers have discovered that in 45 COVID-19 patients admitted in the intensive care unit in a German hospital, testosterone plays a crucial role in their survival against the deadly virus.

Researchers found that the broad majority of men admitted had significantly low testosterone levels. Without an ample supply of the sex hormone, the body won't be able to regulate its immune response, which could lead to a deadly 'cytokine storm.' They have found that testosterone may be capable of keeping the body's immune system from going out of control.

In the study, the researchers evaluated the first 45 COVID-19-positive patients admitted to the ICU at the University Medical Center Hamburg-Eppendorf. Thirty-five of the patients were men, while ten were women. Seven of the patients required oxygen, and 33 of them required the use of ventilation.

Before the patients received any invasive procedures, their hormone levels were assessed on their first day of admission to the ICU. Samples from the patients were tested for 12 hormones, along with testosterone and dihydrotestosterone.

Of the male COVID-19 patients sent to ICU at the German hospital, more than 68% recorded low levels of testosterone. On the contrary, the majority of female patients had elevated testosterone levels. Of all the participants in the study, nine men and three women died.

Although low levels of testosterone can not curb the immune response in men, the study found that in female COVID-19 patients, higher testosterone levels were linked to a more compelling inflammatory response.

The sex hormone is known to aid in controlling the body's immune response. However, when a man has low levels of testosterone, the immune system is not at its best and can lead to further damage when contracting an infection.

This could possibly lead to a so-called cytokine storm, which occurs when the immune system goes berserk as it tries to kill the pathogen. A cytokine storm eventually begins injuring the body itself and, if left alone, can cause death.

Read Also: Testicles Are Serving as 'Reservoirs' For Coronavirus Making Men More At Risk of Longer and Severe Case of COVID-19: Study

Hypogonadism in men is a condition where the body doesn't produce enough of the sex hormone, testosterone. The hormone plays a crucial role in masculine growth and development during puberty.

Some men are born with hypogonadism, while others develop them later on in life, usually from infection or injury. Some types of the condition can be treated with testosterone replacement therapy.

The condition can undoubtedly reduce the quality of life and, in some cases, has resulted in the loss of livelihood and separation of couples. Testosterone has many vital actions involved in metabolism, vasculature, and brain function. Furthermore, the hormone also has well-known effects on bone and body composition.

Statistics prove that coronavirus seems to hit men harder than women. Experts say that some of it may be due to the behavior of men when it comes to tobacco smoke and drinking alcohol. Such lifestyle and behavior could predispose them to have more underlying diseases than women.

Another behavioral factor to consider is that men tend to seek medical care later in the course of disease than women do. Most women tend to act fast and consult their physicians right away, while men display the 'macho' attitude and avoid going to see their doctor as much as possible.

Biological factors could play a part in this too. Professionals say that men have weaker immune systems and that sex hormones involved in the process of how the immune system starts an inflammatory response to pathogens may also be involved.

Also Read: COVID-19 Male Patients to Receive Female Sex Hormones Estrogen and Progesterone To See if They Could Help Reduce Severity

Go here to see the original:
Men With Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Fi - Science Times

Male Hypogonadism Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Cole of Duty

Therapeuticsmd

Moreover, the Male Hypogonadism Therapy report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Male Hypogonadism Therapy market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Male Hypogonadism Therapy market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=222164&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Male Hypogonadism Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Male Hypogonadism Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Male Hypogonadism Therapy Market, By Deployment Model

5.1 Overview

6 Male Hypogonadism Therapy Market, By Solution

6.1 Overview

7 Male Hypogonadism Therapy Market, By Vertical

7.1 Overview

8 Male Hypogonadism Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Male Hypogonadism Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=222164&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Male Hypogonadism Therapy Market Size, Male Hypogonadism Therapy Market Trends, Male Hypogonadism Therapy Market Growth, Male Hypogonadism Therapy Market Forecast, Male Hypogonadism Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Autonomous Cars Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hybrid Train Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to read the rest:
Male Hypogonadism Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Male Hypogonadism Market to Witness over CAGR Growth in Revenue During the COVID-19 Pandemic – Germany English News

Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

3d Cell Cultures Market3d Cell Cultures Market Segmented By Extracellular Matrices or Scaffolds, Bioreactors, Gels, Scaffold-free Platforms, Microchips Technology in Research, Drug development and testing, Tissue engineering, Clinical application, Stem cell biology.For More Information.

Cranio Maxillofacial Implants MarketCraniomaxillofacial Implants Market Segmented By Plate and Screw Fixation Systems, Distraction Systems, Temporomandibular Joint Replacement Devices, Flap Fixation Devices and Bone Graft Substitutes with Calcium Ceramics, Polymers, Metals and Alloys, Biological Materials.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Follow this link:
Male Hypogonadism Market to Witness over CAGR Growth in Revenue During the COVID-19 Pandemic - Germany English News

Androgen Replacement Therapy Market 2020 Coronavirus (Covid-19) Business Impact Future Forecast Assessed On The Basis Of How The Market Is Predicted…

The global Androgen Replacement Therapy Market research report thoroughly explains each and every aspect related to the Androgen Replacement Therapy Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of thorough examination offers in-depth information regarding the global Androgen Replacement Therapy Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Androgen Replacement Therapy Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/3787

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalAndrogen Replacement TherapyMarket Includes:AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddys Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.

Regions & Countries Mentioned In The Androgen Replacement Therapy Market Report:

Key Highlights of the Table of Contents:

Androgen Replacement Therapy Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Androgen Replacement Therapy Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Androgen Replacement Therapy Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Androgen Replacement Therapy Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3787

Table of Contents

Report Overview:It includes the Androgen Replacement Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Androgen Replacement Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Androgen Replacement Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Androgen Replacement Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/3787

Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.SPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Excerpt from:
Androgen Replacement Therapy Market 2020 Coronavirus (Covid-19) Business Impact Future Forecast Assessed On The Basis Of How The Market Is Predicted...

COVID-19 Testing Continues to Lift Aytu BioScience Stock – 24/7 Wall St.

Healthcare Business

Chris Lange

Aytu BioScience Inc. (NASDAQ: AYTU) has been a stock market darling since it broke onto the COVID-19 testing scene. As a result, the stock has absolutely exploded this year. Although many were concerned at the onset of the year about Nasdaq compliance, the stock price quickly quieted these concerns when COVID-19 hit the scene.

Aytu BioScience stock traded as low as $0.34 a share in February before it came out with a test to help fight the pandemic. Since then, the shares have reached as high as $2.99, but they have normalized and found a trading range between $1.25 and $1.65.

Testing for the coronavirus has become a lucrative field. Other companies specifically dealing with this include Quest Diagnostics Inc. (NYSE: DGX), Co-Diagnostics Inc. (NASDAQ: CODX) and Becton, Dickinson and Co. (NYSE: BDX). Their stocks have seen solid gains since they entered the coronavirus test business as well.

Aytu BioScience is a specialty pharmaceutical company. It focuses on the development and commercialization of novel products in the fields of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility.

What has set this company apart from the rest is that it has secured an exclusive distribution agreement for the right to commercialize a rapid COVID-19 test. The company said that the test has been licensed from L.B. Resources in Hong Kong. It licensed North American rights from a product developer named Zhejiang Orient Gene Biotech.

The test is intended for professional use, at point of care. What stands out here is that the test is said to deliver clinical results in two to 10 minutes, wherever it is administered.

Late in April, the company announced that it has partnered with Sterling Medical Devices to finalize the development of the Healight platform technology. Basically, this tech is a novel endotracheal catheter that acts as a potential treatment for the coronavirus.

Management believes the Healight platform technology has the potential to affect outcomes positively for critically ill patients infected with coronavirus and other infections. Aytu, with support of the team at Cedars-Sinai, is working with the U.S. Food and Drug Administration (FDA). The aim is to determine an expedited regulatory process with the potential to enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.

Aytu BioScience held its 2020 annual meeting in late April. A few key developments there will have an impact on the direction of the company. To start, a few new directors will get their turn on the board.

In the meeting, stockholders elected Joshua Disbrow, Steven Boyd, Gary Cantrell, Carl Dockery, John Donofrio Jr., Michael Macaluso and Ketan Mehta to the companys board of directors for one-year terms.

Separately, stockholders approved an advisory vote on executive compensation and ratified the appointment of Plante & Moran as the independent auditor for the company for the 2020 year. Stockholders also approved the board of directors to authorize a reverse split of the companys common stock.

However, the board did not elect to proceed with a reverse stock split at that time. This decision is the result of Aytu regaining compliance with Nasdaq listing requirements, including having a $1.00 closing bid price for the companys common stock. Additionally, the board noted that effecting a reverse split would not be in the best interest of shareholders at the time.

Check out the companys 8-K from this meeting on the U.S. Securities and Exchange Commission website.

Subscribe to Our Newsletter

Read more:
COVID-19 Testing Continues to Lift Aytu BioScience Stock - 24/7 Wall St.

Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update – Yahoo Finance

ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the quarter ended March 31, 2020 on May 14, 2020, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy.

Conference Call Information

1- 877-407-9124 (toll-free)1- 201-689-8584 (international)

The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.

A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 34718.

About Aytu BioScience, Inc.

Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma.

Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human marketing and sales platform.

Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the Company's consumer healthcare products.

Contact for Media and Investors:

James CarbonaraHayden IR(646) 755-7412james@haydenir.com

SOURCE: Aytu BioScience, Inc.

View source version on accesswire.com: https://www.accesswire.com/588844/Aytu-BioScience-to-Report-Fiscal-Q3-FY-2020-Results-and-Business-Update

Read this article:
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update - Yahoo Finance

Male Hypogonadism Therapy Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 – Cole of Duty

Therapeuticsmd

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Male Hypogonadism Therapy market. A competition analysis is imperative in the Male Hypogonadism Therapy market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Male Hypogonadism Therapy across the world has been calculated through primary and secondary research. The Male Hypogonadism Therapy Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=222164&utm_source=NYH&utm_medium=888

Highlights of the Male Hypogonadism Therapy market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Male Hypogonadism Therapy market. Additionally, it includes a share of every segment of the Male Hypogonadism Therapy market, giving methodical information about types and applications of the market.

Key point summary of the Male Hypogonadism Therapy market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Male Hypogonadism Therapy market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Male Hypogonadism Therapy market

Chapter 2: Evaluating the leading manufacturers of the global Male Hypogonadism Therapy market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Male Hypogonadism Therapy market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Male Hypogonadism Therapy market describes Male Hypogonadism Therapy industry expansion game plan, the Male Hypogonadism Therapy industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=222164&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Male Hypogonadism Therapy Market Size, Male Hypogonadism Therapy Market Trends, Male Hypogonadism Therapy Market Growth, Male Hypogonadism Therapy Market Forecast, Male Hypogonadism Therapy Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Needle Free Injection Systems Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Needles Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Male Hypogonadism Therapy Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 – Jewish Life News

Given the debilitating impact of COVID-19 (Coronavirus) on the Male Hypogonadism market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Male Hypogonadism market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Male Hypogonadism Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Male Hypogonadism market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Male Hypogonadism market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Male Hypogonadism market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/22303

Regional Overview

Our team of analysts at PMR, trace the major developments within the Male Hypogonadism landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Male Hypogonadism market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/22303

Key Takeways Enclosed in the Report:

Queries Related to the Male Hypogonadism Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/22303

Why Opt for Persistence Market Research?

Read the original:
The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 - Jewish Life News

Testosterone Cypionate Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:…

Testosterone Cypionate Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Testosterone Cypionate Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/1617548/testosterone-cypionate-market

The Testosterone Cypionate Market report next half additionally sheds explore on the gap between supply and consumption. Apart from the mentioned industry growth rate of market in 2025is also explained. In addition, type wise and application wise consumption tables and figures of Testosterone Cypionate market are given..

The Testosterone Cypionate market report covers major market players like Pfizer, Cipla, Sun Pharmaceutical, Teva, Perrigo, Hikma Pharmaceuticals

Performance Analysis of Testosterone Cypionate Industry 2020 Highlighting Recent Market Growth, Trends and Development 2026 Forecast Report. The Testosterone Cypionate Market report also studies the manufacturing cost structure and presents the various details such as raw material, the overall production process, and the industry chain structure.

Get Exclusive Free Sample of Report on Testosterone Cypionate market is available at https://inforgrowth.com/sample-request/1617548/testosterone-cypionate-market

Global Testosterone Cypionate Market Research Report 2020 is a comprehensive business study on the current state of the industry which analyses innovative strategies for business growth and describes important factors such as top manufacturers, production value, key regions, and growth rate.

Testosterone Cypionate Market 2020-2025: Segmentation

Testosterone Cypionate Market is segmented as below:

Breakup Product Type:200 mg/mL, 100 mg/mL

Breakup by Application:Primary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism

Geographic segmentation

To know about the global trends impacting the future of market research, contact at: https://inforgrowth.com/enquiry/1617548/testosterone-cypionate-market

Testosterone Cypionate Market 2020-2025: Scope

We present a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

OurTestosterone Cypionate marketreport covers the following areas:

Key Reasons to Purchase The Testosterone Cypionate Market Report:

1 To gain insightful analyses of the Testosterone Cypionate Market and have comprehensive understanding of the Global Market and its commercial landscape2 Assess the production processes, major issues, and solutions to mitigate the development risk.3 To understand the most affecting driving and restraining forces in the market and its impact in the Global Testosterone Cypionate Market.4 Learn about the market strategies that are being adopted by leading respective organizations.5 To understand the future outlook and prospects for the Testosterone Cypionate Market.6 Besides the standard structure reports, we also provide custom research according to specific requirements.

Get Special Discount UP TO 50% for this Report: https://inforgrowth.com/discount/1617548/testosterone-cypionate-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See more here:
Testosterone Cypionate Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:...

Recent Facts that led Male Hypogonadism Market on top by 2027 with Top Key Players like AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli…

Male hypogonadism is a failure of the testes that produce the male test hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland. The male hypogonadism market is anticipated to grow owing to increasing case of testosterone deficiency among men. However, high side effects is one of the major restraints for the market growth. Moreover, rising geriatric population all across the world coupled with rising cases of obesity and rheumatoid arthritis are expected to benefit the growth of the market in the forecast period.

Some of the key players of Male Hypogonadism Market:AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Finox Biotech,, Laboratoires Genevrier, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00013261048/sample

The Global Male Hypogonadism Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report.

Segmentation by product type:Klinefelters Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

Segmentation by Drug Delivery:Topical Gels

Injectable

Transdermal Patches

Others

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00013261048/discount

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Male Hypogonadism market based on product and application. It also provides market size and forecast till 2027 for overall Male Hypogonadism market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Male Hypogonadism Market Size2.2 Male Hypogonadism Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Male Hypogonadism Market Size by Manufacturers3.2 Male Hypogonadism Key Players Head office and Area Served3.3 Key Players Male Hypogonadism Product/Solution/Service3.4 Date of Enter into Male Hypogonadism Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Male Hypogonadism Sales by Product4.2 Global Male Hypogonadism Revenue by Product4.3 Male Hypogonadism Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Male Hypogonadism Breakdown Data by End User

Continue for TOC

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00013261048/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Read the original:
Recent Facts that led Male Hypogonadism Market on top by 2027 with Top Key Players like AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli...

Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet…

The global Male Hypogonadism Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism Therapy market player in a comprehensive way. Further, the Male Hypogonadism Therapy market report emphasizes the adoption pattern of the Male Hypogonadism Therapy across various industries.

The Male Hypogonadism Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Male Hypogonadism Therapy market provides a birds eye view of the current proceeding within the Male Hypogonadism Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Male Hypogonadism Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2619190&source=atm

The key players covered in this studyEli LillyPfizerAbbVieNovo NordiskMerck KGaAMylanBayerTevaNovartisAbbottRocheEndo InternationalIpsenANI PharmaceuticalsTherapeuticsMD

Market segment by Type, the product can be split intoParenteralTransdermalOralOthersMarket segment by Application, split intoHospitalsDrugstoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Male Hypogonadism Therapy status, future forecast, growth opportunity, key market and key players.To present the Male Hypogonadism Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Male Hypogonadism Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2619190&source=atm

The Male Hypogonadism Therapy market report offers a plethora of insights which include:

The Male Hypogonadism Therapy market report answers important questions which include:

The Male Hypogonadism Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2619190&licType=S&source=atm

Why Choose Male Hypogonadism Therapy Market Report?

Male Hypogonadism Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See original here:
Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet...

Archives